Cargando…
The Aastrom experience
Aastrom Biosciences has developed a proprietary cell-processing technology that enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a small sample of a patient's own bone marrow. Ixmyelocel-T is produced under current good manufacturing practices (cGM...
Autores principales: | Bartel, Ronnda L, Cramer, Caryn, Ledford, Kelly, Longcore, Amy, Parrish, Christopher, Stern, Theresa, Watling, Sharon, Zeigler, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580464/ https://www.ncbi.nlm.nih.gov/pubmed/22776246 http://dx.doi.org/10.1186/scrt117 |
Ejemplares similares
-
From Bench to Bedside: Review of Gene and Cell-Based Therapies and the Slow Advancement into Phase 3 Clinical Trials, with a Focus on Aastrom’s Ixmyelocel-T
por: Bartel, Ronnda L., et al.
Publicado: (2013) -
Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages
por: Ledford, Kelly J, et al.
Publicado: (2013) -
Potential beneficial effects of ixmyelocel-T in the treatment of atherosclerotic diseases
por: Ledford, Kelly J, et al.
Publicado: (2013) -
Therapeutic potential of ixmyelocel-T, an expanded autologous multicellular therapy for treatment of ischemic cardiovascular diseases
por: Ledford, Kelly J, et al.
Publicado: (2015) -
Surgical Outreach for Children by International Humanitarian Organizations: A Review
por: Kynes, J. Matthew, et al.
Publicado: (2017)